ArticleBrain and behavior2025
Evaluation of CD3+CD56+ NKT and CD19+ B Cells in Assessing the Relapse of Neuromyelitis Optica Spectrum Disorder Patients Treated With Rituximab.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe purpose of this study was to explore the value of pre-treatment levels of CD3+CD56+ NKT cells and CD19+ B cells in evaluating the relapse of patients with neuromyelitis optica spectrum disorders (NMOSD) treated with rituximab.
methodsA total of 166 NMOSD patients admitted to our hospital from January 2021 to August 2022 were included in this study. All patients received rituximab and were followed up for 1 year. Based on their relapse status, patients were categorized into a relapse group (n = 10) and a non-relapse group (n = 156). Peripheral venous blood samples were collected, and the pre-treatment levels of CD3+CD56+ NKT and CD19+ B cells were measured using flow cytometry. Logistic regression analysis was used to identify factors influencing relapse, and receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of these cells for relapse.
resultsThe relapse group had significantly lower levels of CD3+CD56+ NKT cells and higher levels of CD19+ B cells compared to the non-relapse group (p < 0.05). Multivariate analysis confirmed that lower pre-treatment CD3+CD56+ NKT cell levels (OR = 1.549, 95% CI: 1.068-2.199; p = 0.001) and higher CD19+ B cell levels (OR = 1.272, 95% CI: 1.039-1.758; p = 0.002) were potential independent predictors of relapse. ROC curve analysis showed that the combined model yielded a modest predictive value (AUC = 0.652, p < 0.05), which was statistically superior to that of either biomarker alone. During follow-up, rituximab was generally well-tolerated, with infusion-related reactions (18.1%) and infections (11.4%) being the most common adverse events.
conclusionPre-treatment levels of CD3+CD56+ NKT cells and CD19+ B cells are potential markers for evaluating the risk of relapse in NMOSD patients treated with rituximab, although their predictive accuracy is modest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.